Milataxel

Milataxel (MAC-321) is an orally active taxane analog of Docetaxel (HY-B0011) . Milataxel enhances the rate of tubulin polymerization. Milataxel can be used in the research of colorectal cancer and non-small cell lung cancer[1][2].

Product Specifications

CAS Number

[393101-41-2]

Product Name Alternative

MAC-321

UNSPSC

12352005

Target

Drug Derivative; Microtubule/Tubulin

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

O=C(O[C@@H]1C(C)=C(C(C)2C)[C@@H](O)C([C@@]([C@@H](OC(CC)=O)C3)(C)C([C@@]4(OC(C)=O)[C@]3([H])OC4)[C@H](OC(C5=CC=CC=C5)=O)[C@]2(O)C1)=O)[C@H](O)[C@@H](NC(OC(C)(C)C)=O)C6=CC=CO6

Molecular Formula

C44H55NO16

Molecular Weight

853.90

References & Citations

[1]Ramanathan RK, et al. A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2008 Mar;61 (3) :453-8. |[2]Mekhail T, et al. A phase II study of intravenous (IV) milataxel (M) for the treatment of non-small cell lung cancer (NSCLC) refractory to platinum-based therapy. Journal of Clinical Oncology, 2006, 24 (18_suppl) : 7098-7098.